Resources from the same session
7MO - Sotorasib in <italic>KRAS</italic> G12C–mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)
Presenter: Natalie Maimon
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
8MO - Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Presenter: Pasi Jänne
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
143MO - Risk of lung cancer among current smokers by pack-year smoking: A cohort study with 23 years of follow-up
Presenter: Joel Nations
Session: Mini Oral 1
Resources:
Abstract
9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer
Presenter: Maria Saigi Morgui
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
145MO - Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Presenter: David Carbone
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 9MO and 145MO
Presenter: Fernando Lopez-Rios
Session: Mini Oral 1
Resources:
Slides
Webcast